Effects of Biktarvy on CFR in Stable HIV Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 14, 2018

Primary Completion Date

September 15, 2021

Study Completion Date

September 15, 2021

Conditions
HIV
Interventions
DRUG

Biktarvy

Open-label, multicenter, single-arm study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Abacavir/Lamivudine/Dolutegravir (ABC/3TC/DTG) to the Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV-Infected Adult Subjects

Trial Locations (3)

02111

Tufts Medical Center, Boston

02115

Brigham and Women's Hospital, Boston

02118

Boston Medical Center, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Tufts Medical Center

OTHER

collaborator

Boston Medical Center

OTHER

lead

Brigham and Women's Hospital

OTHER